XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.2
REVENUES (Tables)
 9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
Contract with Customer, Contract Asset
The following table summarizes our contract assets:
(in millions)September 30,
2021		December 31,
2020
Contract manufacturing services$73 $47 
Software sales38 40 
Bundled equipment and consumable medical products contracts82 47 
Contract assets$193 $134 
The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:
(in millions)September 30,
2021		December 31,
2020
Prepaid expenses and other current assets$104 $70 
Other non-current assets89 64 
Contract assets$193 $134 
Accrued expenses and other current liabilities$39 $32 
Other non-current liabilities52 34 
Contract liabilities$91 $66 
Net Sales from Contracts with Customers by Global Business Unit
The following tables disaggregate our net sales from contracts with customers by product category between the U.S. and international:
Three Months Ended September 30,
20212020
(in millions)U.S.InternationalTotalU.S.InternationalTotal
Renal Care 1
$222 $759 $981 $216 $739 $955 
Medication Delivery 2
490 257 747 419 246 665 
Pharmaceuticals 3
188 401 589 209 330 539 
Clinical Nutrition 4
88 156 244 87 147 234 
Advanced Surgery 5
135 114 249 138 97 235 
Acute Therapies 6
69 116 185 72 105 177 
BioPharma Solutions 7
109 97 206 84 57 141 
Other 8
18 7 25 19 7 26 
Total Baxter$1,319 $1,907 $3,226 $1,244 $1,728 $2,972 

Nine Months Ended September 30,
20212020
(in millions)U.S.InternationalTotalU.S.InternationalTotal
Renal Care 1
$655 $2,212 $2,867 $629 $2,115 $2,744 
Medication Delivery 2
1,345 751 2,096 1,262 686 1,948 
Pharmaceuticals 3
550 1,137 1,687 637 899 1,536 
Clinical Nutrition 4
255 460 715 241 426 667 
Advanced Surgery 5
405 317 722 369 258 627 
Acute Therapies 6
211 369 580 204 315 519 
BioPharma Solutions 7
218 306 524 186 185 371 
Other 8
58 21 79 60 20 80 
Total Baxter$3,697 $5,573 $9,270 $3,588 $4,904 $8,492 

1Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services.
2Medication Delivery includes sales of our intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices.
3Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services.
4Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products.
5Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.
6Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU).
7BioPharma Solutions includes sales of contracted services we provide to various pharmaceutical and biopharmaceutical companies.
8Other includes sales of miscellaneous product and service offerings.
Sales-type Lease, Lease Income
The components of lease revenue for the three and nine months ended September 30, 2021 were:
(in millions)Three months ended September 30, 2021Nine months ended September 30, 2021
Sales-type lease revenue$3 $19 
Operating lease revenue21 90 
Variable lease revenue27 59 
Total lease revenue$51 $168 
The components of lease revenue for the three and nine months ended September 30, 2020 were:
(in millions)Three months ended September 30, 2020Nine months ended September 30, 2020
Sales-type lease revenue$11 $27 
Operating lease revenue16 44 
Variable lease revenue19 57 
Total lease revenue$46 $128 
Operating Lease, Lease Income
The components of lease revenue for the three and nine months ended September 30, 2021 were:
(in millions)Three months ended September 30, 2021Nine months ended September 30, 2021
Sales-type lease revenue$3 $19 
Operating lease revenue21 90 
Variable lease revenue27 59 
Total lease revenue$51 $168 
The components of lease revenue for the three and nine months ended September 30, 2020 were:
(in millions)Three months ended September 30, 2020Nine months ended September 30, 2020
Sales-type lease revenue$11 $27 
Operating lease revenue16 44 
Variable lease revenue19 57 
Total lease revenue$46 $128